Ariad axes 90 staffers in ongoing reorg

Cambridge, MA-based Ariad Pharmaceuticals ($ARIA) is axing about 90 staffers--25% of its total workforce--in an ongoing restructuring of the business. The biotech is also reviewing its R&D portfolio and other aspects of the business, saying it plans to unveil more changes in Q2. Ariad says it is concentrating efforts around its once-suspended cancer drug Iclusig as well as the late-stage drug brigantinib. Brigantinib, its only other clinical asset, is in pivotal studies for non-small cell lung cancer. Ariad laid off 40% of its staff in 2013 when it was forced to yank its leukemia drug off the market. Release

Suggested Articles

A new biotech has come out of stealth with a funding round that includes “celebrity investors in artificial intelligence” as it aims to tackle aging.

GSK filed for patents on the lentiviral stable cell line technology before selling its rare disease gene therapy portfolio to Orchard in 2018.

The update, which could come as soon as tomorrow, may shed light on how the front-runner vaccine fared in early clinical trials.